View Older Stories View More Recent Stories
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
RBC Capital Upgrades PTC Therapeutics (PTCT) to Outperform, 'NVS HD Deal Meaningfully Improves Fundamentals'
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics (PTCT) PT Raised to $46 at RBC Capital
-
RBC Capital on PTC Therapeutics (PTCT): 'Data Should Be Good Enough for Translarna to Stay on EU Mkt'
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
-
UPDATE: RBC Capital Downgrades PTC Therapeutics (PTCT) to Underperform
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
RBC Capital Downgrades PTC Therapeutics (PTCT) to Sector Perform
-
PTC Therapeutics (PTCT) PT Raised to $58 at RBC Capital
-
UPDATE: PTC Therapeutics (PTCT) Management Conversation Implies Upside From Gene Therapy - RBC Capital
-
PTC Therapeutics (PTCT) PT Raised to $50 at RBC Capital
-
PTC Therapeutics to Participate at Upcoming Investor Conferences
-
PTC Therapeutics (PTCT) PT Raised to $42 at RBC Capital
-
PTC Therapeutics (PTCT) Risdiplam's Competitive Potential Highlighted - RBC
-
PTC Therapeutics Announces Partial Exercise of Underwriter's Option to Purchase Additional Shares
-
PTC Therapeutics (PTCT) PT Raised to $40 at RBC Capital Following Deep Dive
-
Pre-Open Stock Movers 01/23: (ATHX) (SYF) (RIGL) Higher; (BLPH) (TSE) (PTCT) Lower (more...)
-
PTC Therapeutics (PTCT) Prices 6.72M Common Stock Offering at $30.20/Share
-
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
-
PTC Therapeutics (PTCT) to Offer $200M in Common Stock
-
PTC Therapeutics Announces Proposed Public Offering of Common Stock
-
PTC Therapeutics (PTCT) PT Lowered to $46 at RBC Capital
-
RBC Capital Remains Bullish on PTC Therapeutics (PTCT) Following Waylivra CRL
-
PTC Therapeutics (PTCT) PT Raised to $51 at RBC Capital
-
RBC Capital Upgrades PTC Therapeutics (PTCT) to Outperform Following 'Compelling' SMA Data
-
RBC Positive on Biogen (BIIB) Karp Hire Amid Partnerships/M&A Potential
-
Roche's SMA Update is 'Incrementally Positive' for PTC Therapeutics (PTCT) - RBC
-
PTC Therapeutics (PTCT) PT Lowered to $30 at RBC Capital
-
PTC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
-
PTC Therapeutics (PTCT) Prices 4M Share Offering at $27.04/Sh
-
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
-
PTC Therapeutics (PTCT) Commences 4M Share Offering of Common Stock
-
PTC Therapeutics Announces Proposed Public Offering of Common Stock
-
PTC Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
-
Pre-Open Movers 01/29: (IMMR) (DPS) (KS) Higher; (CYOU) (SOHU) (ADNT) Lower (more...)
-
RBC Capital Assumes PTC Therapeutics (PTCT) at Sector Perform
-
PTC Therapeutics (PTCT) Announces Departure of CFO, Shane Kovacs
-
PTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs
-
RBC Capital Maintains Sector Perform and $13 PT on PTC Therapeutics (PTCT); NDA for Ataluren Filed Under Protest with FDA
-
PTC Therapeutics' (PTCT) Price Target Raised to $13 at RBC Capital
-
RBC Affirms PTC Therapeutics (PTCT) at 'Sector Perform'; Doesn't See Translarna Appeal with Solid Chance
-
PTC Therapeutics (PTCT) NICE-Related News a Positive, But Could Be 'Short-Lived' - RBC
-
RBC Cuts PTC Therapeutics (PTCT) Price Target by Nearly 20%
-
Pre-Open Stock Movers 02/25: (POWR) (GTLS) (TREE) (CRM) Higher; (RATE) (RH) (RLYP) Lower (more...)
-
RBC Capital Downgrades PTC Therapeutics (PTCT) to Sector Perform
-
PTC Therapeutics to Participate at Upcoming Investor Conferences

